FDA Approved: MYLOTARG — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)

View source ↗

Summary

The FDA approved a supplemental application for MYLOTARG (gemtuzumab ozogamicin) submitted by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

SUPPL AP for MYLOTARG (GEMTUZUMAB OZOGAMICIN)